RxDoctor Payments Data

Kristin Lee, APRN

Family · Bowling Green, KYNPI 1649897497

Payments from drug & device makers

$9,492in general payments, 2019–2025

Across 442 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • UCB, Inc.$1K
  • AbbVie$1K
  • Novartis$980
  • Mallinckrodt Hospital Products Inc.$600
  • Johnson & Johnson$547
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$9,39199%
  • Education$1011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,492 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$226,963
Medicare patients
206
Services billed
6,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ActharCorticotropin37$2,493,485
Enbrel SureclickEtanercept88$652,814
Humira(Cf) PenAdalimumab93$628,738
OtezlaApremilast59$285,617
RinvoqUpadacitinib32$228,157
Cosentyx Sensoready (2 Pens)Secukinumab30$221,597
Gamunex-CImmune Globul G/Gly/Iga Avg 4624$181,584
BenlystaBelimumab15$71,855
TymlosAbaloparatide25$66,524
Azathioprine35$9,824
Leflunomide145$7,065
MethotrexateMethotrexate Sodium453$6,224
Hydroxychloroquine Sulfate272$6,135
Celecoxib79$2,945
Colchicine26$2,578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Mallinckrodt Hospital Products Inc.Acthar$600$2,493,48537 claims
AmgenOtezla$2,121$285,61759 claims
AbbVieRinvoq$1,126$228,15732 claims
GSKBenlysta$547$71,85515 claims
Radius Health, Inc.Tymlos$259$66,52425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →